Monitoring and evaluation of the efficacy and safety of Artesunate-Mefloquine with a low single dose of Primaquine for the treatment of uncomplicated Plasmodium malaria in Cambodia

It is a single arm open-label study to evaluate therapeutically efficacy and safety of Artesunate-Mefloquine for the treatment of P. falciparum malaria. Eligible patients were treated with a daily dose of 1 tablet for 18-29 kg, and 2 tablets for 30 kg body weight over 3 days. One tablet contains 100 mg Artesunate plus 220mg Mefloquine. The patients took the drugs in front of the field-based medical doctor and a complete dose was repeated if a patient vomited within 30 minutes following the drug administration. A blood smear was examined by the microscope on a daily basis until a patient became negative over 2 consecutive days. Then, the patients were asked to return to the study site once a week over 42 days. A home visit was made when any patient missed the appointment.